This study focuses on people who are at risk for or in the early stages of Alzheimer’s Disease, a brain condition that affects memory and thinking abilities. The research will test a new medication called RO7269162, which is taken as oral capsules, comparing it with a placebo to understand how well it works and how safe it is. The study aims to examine how this medication affects various markers of brain health, particularly the buildup of amyloid, a protein associated with Alzheimer’s Disease.

During the study, participants will receive either RO7269162 or placebo capsules to take daily for up to 72 weeks. To monitor brain changes, participants will undergo PET scans using special imaging substances called florbetaben or flutemetamol, which are given through slow injection into a vein. These substances help make brain amyloid visible during the scanning procedure.

Throughout the study, various health measurements will be taken to ensure participant safety and to understand how the medication affects the body. This includes monitoring vital signs, conducting medical tests, and collecting samples to measure the levels of different substances in the blood and spinal fluid that are related to Alzheimer’s Disease.